Recursion Pharmaceuticals Inc (RXRX)
8.945
+0.10
(+1.19%)
USD |
NASDAQ |
May 06, 16:00
8.945
0.00 (0.00%)
After-Hours: 20:00
Recursion Pharmaceuticals Cash and Short Term Investments (Quarterly): 391.56M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 391.56M |
| September 30, 2023 | 387.32M |
| June 30, 2023 | 405.87M |
| March 31, 2023 | 473.14M |
| December 31, 2022 | 549.91M |
| September 30, 2022 | 454.65M |
| June 30, 2022 | 515.44M |
| Date | Value |
|---|---|
| March 31, 2022 | 591.10M |
| December 31, 2021 | 516.56M |
| September 30, 2021 | 578.91M |
| June 30, 2021 | 632.74M |
| March 31, 2021 | 214.09M |
| December 31, 2020 | 262.13M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
214.09M
Minimum
Mar 2021
632.74M
Maximum
Jun 2021
459.49M
Average
473.14M
Median
Mar 2023
Cash and Short Term Investments (Quarterly) Benchmarks
| Eli Lilly and Co | 2.586B |
| Palatin Technologies Inc | 9.485M |
| Oragenics Inc | 3.484M |
| Actinium Pharmaceuticals Inc | 84.06M |
| Marinus Pharmaceuticals Inc | 150.29M |